NCT03647592View on ClinicalTrials.gov

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

August 31, 2024

Study Completion Date

December 1, 2025

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Erlotinib/Gefitinib combined with Bevacizumab

Erlotlnib,150mg po qd/gefitinib 250mg po qd +Bevacizumab(15mg/kg),lvgtt,every 21 day ,evaluate every 2 months

Trial Locations (1)

410013

RECRUITING

Hunan Provincal Tumor Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER